NEWSROOM
Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings
January 13-16, 2025, San Francisco, CA IRVINE, Calif., December 9, 2024 - PRISM MediaWire - Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13 - 16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors....
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
Klotho Neurosciences, Inc. continues to strengthen its advisory teams with recent new additions of Neuroscience and Big Pharma leaders to Scientific Advisory Board and Board of Directors New York, NY, December 9, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral sclerosis (ALS), Alzheimer’s and Parkinson’s disease is proud to announce the appointment of Dr. Merit Cudkowicz,...
SKYX to Conduct a Company Presentation at Benchmark Conference on December 11, 2024, at 3:30pm
Rani Kohen, Founder, and Lenny Sokolow, Co-CEO of SKYX, to Present at 3:30 PM ET on December 11, 2024, and Engage in Investor Meetings Throughout the Conference at the New York Athletic Club MIAMI, December 9, 2024 - PRISM MediaWire - SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a "SKYX Technologies"), a highly disruptive smart platform technology company with over 97 issued and pending patents in the U.S. and globally, and over 60 lighting and home décor websites with a mission to make homes and...
BranchOut Food Inc. Signs LOI and receives $250K PO from Leading Ingredient Distributor, Definitive Agreement Targeting $5-6M in 2025 Ingredient Sales
Projecting $4.0M in net revenue for Q1 2025—up 170% from the prior year—and expects to achieve positive cash flow in the same quarter Key Highlights: Signed LOI with leading ingredient distributor, establishing immediate sales volume in the ingredient channel. Received an initial $250,000 purchase order alongside the LOI. Anticipating completing a Definitive Agreement in January with a minimum commitment of $5M in sales for 2025. New Peru factory’s three production lines are now fully...
Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study
IRVINE, Calif., Dec. 04, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a paper recently published in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number...
Former Merck USA President Joins Klotho Neurosciences’ Board of Directors
Highly Accomplished Pharmaceutical Leader, Riad El-Dada, Further Enhances Board Expertise NEW YORK, Dec. 03, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related disorders, including ALS, Alzheimer’s, and Parkinson’s, today announced the appointment of Riad El-Dada, former US President of Merck, to its Board of Directors. With decades of leadership in the pharmaceutical...
AB INTL Group Announces Repurchase of 300 Million Shares and Planning Spin-off of NFT MMM IP and AI Consulting Business
NEW YORK, Dec. 03, 2024 - PRISM MediaWire - AB International Group Corp. (OTC: ABQQ), an intellectual property (IP) and movie investment and licensing firm, today announced the Company entered into Repurchase Agreements with four shareholders, all non-affiliates of the Company, pursuant to which the Company agreed to repurchase shares of their Common Stock, $0.001 par value, amounting to 300,000,000 shares for cancellation. The price to be paid by the Company under the Repurchase Agreements is...
Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus
Peer-reviewed article highlights potential treatment for OLP with focus on localized drug delivery PITTSBURGH, Dec. 03, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage biotechnology company dedicated to addressing serious diseases with significant unmet needs, today announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical Calcineurin Inhibitors in the Management of Oral Lichen Planus and Mucosal...
Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms
Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population Study shows that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection. Study published in Nephrology Dialysis...
Halberd Update on WatchDawg® PTSD Treatment
Next Phase Pilot Study Jackson Center, PA, December 2, 2024 - PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here. Based on the encouraging results of that initial pilot study, upgrades and enhancements to the data collection methodology, data analysis, hardware, software...